Profile: Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

618.95INR
19 Dec 2014
Price Change (% chg)

Rs-6.40 (-1.02%)
Prev Close
Rs625.35
Open
Rs632.00
Day's High
Rs634.45
Day's Low
Rs616.85
Volume
1,260,103
Avg. Vol
1,895,986
52-wk High
Rs673.00
52-wk Low
Rs366.50

Search Stocks
Cipla Limited is a pharmaceutical company. During the fiscal year ended March 31, 2012 (fiscal 2012), it introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure. In July 2013, the Company acquired Cipla Medpro South Africa Limited. In November 2013, the Company’s wholly owned step down subsidiary Meditab Holdings Limited, acquired an additional 14.5% interest in Quality Chemical Industries Limited (QCIL) and now held 51.05% interest in QCIL.

Company Address

Cipla Ltd

Mumbai Central
MUMBAI     400008
P: +9122.23082891
F: +9122.23070013

Search Stocks